Nuvectis Pharma Statistics
Total Valuation
Nuvectis Pharma has a market cap or net worth of $618.85 million. The enterprise value is $593.72 million.
| Market Cap | 618.85M |
| Enterprise Value | 593.72M |
Important Dates
The next estimated earnings date is Tuesday, August 4, 2026, before market open.
| Earnings Date | Aug 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Nuvectis Pharma has 31.53 million shares outstanding. The number of shares has increased by 26.31% in one year.
| Current Share Class | 31.53M |
| Shares Outstanding | 31.53M |
| Shares Change (YoY) | +26.31% |
| Shares Change (QoQ) | +0.94% |
| Owned by Insiders (%) | 36.00% |
| Owned by Institutions (%) | 14.49% |
| Float | 20.18M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 36.62 |
| P/TBV Ratio | 43.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.27
| Current Ratio | 2.27 |
| Quick Ratio | 2.25 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -154.43% and return on invested capital (ROIC) is -100.45%.
| Return on Equity (ROE) | -154.43% |
| Return on Assets (ROA) | -63.61% |
| Return on Invested Capital (ROIC) | -100.45% |
| Return on Capital Employed (ROCE) | -198.78% |
| Weighted Average Cost of Capital (WACC) | 2.89% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.47M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +160.35% in the last 52 weeks. The beta is -0.25, so Nuvectis Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.25 |
| 52-Week Price Change | +160.35% |
| 50-Day Moving Average | 12.58 |
| 200-Day Moving Average | 8.77 |
| Relative Strength Index (RSI) | 57.77 |
| Average Volume (20 Days) | 544,656 |
Short Selling Information
The latest short interest is 1.57 million, so 4.98% of the outstanding shares have been sold short.
| Short Interest | 1.57M |
| Short Previous Month | 1.58M |
| Short % of Shares Out | 4.98% |
| Short % of Float | 7.78% |
| Short Ratio (days to cover) | 16.38 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -28.27M |
| Pretax Income | -27.16M |
| Net Income | -29.59M |
| EBITDA | n/a |
| EBIT | -28.27M |
| Earnings Per Share (EPS) | -$1.30 |
Balance Sheet
The company has $25.13 million in cash and n/a in debt, with a net cash position of $25.13 million or $0.80 per share.
| Cash & Cash Equivalents | 25.13M |
| Total Debt | n/a |
| Net Cash | 25.13M |
| Net Cash Per Share | $0.80 |
| Equity (Book Value) | 14.22M |
| Book Value Per Share | 0.54 |
| Working Capital | 14.22M |
Cash Flow
| Operating Cash Flow | -18.35M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Nuvectis Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.31% |
| Shareholder Yield | -26.31% |
| Earnings Yield | -4.78% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Nuvectis Pharma is $31.80, which is 62.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.80 |
| Price Target Difference | 62.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |